Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors.

Hille U, Soergel P, Makowski L, Dörk-Bousset T, Hillemanns P.

Lymphat Res Biol. 2012 Jun;10(2):63-73. doi: 10.1089/lrb.2011.0025.

PMID:
22720661
2.

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.

Transplant Proc. 2010 Oct;42(8):3050-2. doi: 10.1016/j.transproceed.2010.07.083.

PMID:
20970607
3.

Proteinuria associated with mTOR inhibitors after kidney transplant.

Guney M, Sahin G, Yilmaz B, Canbakan M, Gucun M, Kayatas K, Eren P, Titiz I.

Exp Clin Transplant. 2014 Dec;12(6):539-42.

4.

Incidence and treatment of lymphedema in heart transplant patients treated with everolimus.

Ribezzo M, Boffini M, Ricci D, Barbero C, Bonato R, Attisani M, Pasero D, Rinaldi M.

Transplant Proc. 2014 Sep;46(7):2334-8. doi: 10.1016/j.transproceed.2014.07.036.

PMID:
25242782
5.

Everolimus: a new hope for patients with breast cancer.

Sendur MA, Zengin N, Aksoy S, Altundag K.

Curr Med Res Opin. 2014 Jan;30(1):75-87. doi: 10.1185/03007995.2013.846253. Epub 2013 Oct 14. Review.

PMID:
24050600
6.

The pros and the cons of mTOR inhibitors in kidney transplantation.

Ponticelli C.

Expert Rev Clin Immunol. 2014 Feb;10(2):295-305. doi: 10.1586/1744666X.2014.872562. Epub 2013 Dec 30. Review.

PMID:
24377908
7.

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, Stevens M, Elledge R.

Breast Cancer Res Treat. 2014 Jan;143(2):325-32. doi: 10.1007/s10549-013-2810-9. Epub 2013 Dec 11. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(2):565.

PMID:
24327334
8.

Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.

Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H, Riu-Viladoms G, Estefanell-Tejero A, Ribas-Sala J.

Nefrologia. 2013;33(3):297-300. doi: 10.3265/Nefrologia.pre2013.Jan.11439. Review. English, Spanish.

9.

Everolimus in clinical practice in long-term liver transplantation: an observational study.

Casanovas T, Argudo A, Peña-Cala MC.

Transplant Proc. 2011 Jul-Aug;43(6):2216-9. doi: 10.1016/j.transproceed.2011.06.015.

PMID:
21839237
10.

Everolimus: targeted therapy on the horizon for the treatment of breast cancer.

Barnett CM.

Pharmacotherapy. 2012 Apr;32(4):383-96. doi: 10.1002/j.1875-9114.2012.01084.x. Review.

PMID:
22461124
11.

Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.

Gabardi S.

Prog Transplant. 2013 Mar;23(1):55-7. doi: 10.7182/pit2013235.

PMID:
23448821
12.

Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.

Acquazzino MA, Fischer RT, Langnas A, Coulter DW.

Pediatr Transplant. 2013 Aug;17(5):466-71. doi: 10.1111/petr.12101. Epub 2013 Jun 3.

PMID:
23730873
13.

Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.

Schneer S, Kramer MR, Fox B, Rusanov V, Fruchter O, Rosengarten D, Bakal I, Medalion B, Raviv Y.

Clin Transplant. 2014 Jun;28(6):662-8. doi: 10.1111/ctr.12353. Epub 2014 Apr 16.

PMID:
24738962
14.

Can patients maintain their use of everolimus until lung transplantation?

Costa AN, Baldi BG, de Oliveira Braga Teixeira RH, Samano MN, de Carvalho CR.

Transplantation. 2015 Jun;99(6):e42-3. doi: 10.1097/TP.0000000000000722. No abstract available.

PMID:
26035277
15.

Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.

Gabardi S, Baroletti SA.

Pharmacotherapy. 2010 Oct;30(10):1044-56. doi: 10.1592/phco.30.10.1044. Review.

PMID:
20874042
16.

Everolimus: efficacy and safety in cardiac transplantation.

Schaffer SA, Ross HJ.

Expert Opin Drug Saf. 2010 Sep;9(5):843-54. doi: 10.1517/14740338.2010.511611. Review.

PMID:
20701555
18.

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.

Somers MJ, Paul E.

J Clin Pharmacol. 2015 Apr;55(4):368-76. doi: 10.1002/jcph.428. Epub 2014 Dec 30. Review.

PMID:
25402866
19.

Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.

Grgic T, Mis L, Hammond JM.

Ann Pharmacother. 2011 Jan;45(1):78-83. doi: 10.1345/aph.1M288. Epub 2010 Dec 21. Review.

PMID:
21177421
20.

[Lower limb oedema].

Gulich M.

MMW Fortschr Med. 2007 Oct 25;149(43):37-8. German. No abstract available.

PMID:
17999457

Supplemental Content

Support Center